SPARK Biopharma, founded in 2016 in Seoul, South Korea, is a pioneering biotech company specializing in innovative drug discovery and development. At the core of their operations are proprietary platforms such as pDOS Library, Seoul-Fluor, and FITGE/TS-FITGE, which drive their research in immuno-oncology and other therapeutic areas. These technologies enable more efficient drug candidate identification and optimization. Despite its young age, SPARK Biopharma has secured significant funding, including a 25 billion won Series C investment in 2023, fueling its ambitious research projects. With a team of about 30 experts and plans for an IPO in 2024, SPARK Biopharma is positioned to make substantial contributions to biotechnology and drug development, particularly in the field of cancer immunotherapy.

pDOS Library (Phage Display Oligonucleotide Synthesis Library) : The pDOS Library is SPARK Biopharma's primary technology platform. This technology utilizes phage display methods to generate and screen diverse oligonucleotide sequences. It enables rapid and efficient discovery of novel drug candidates. The pDOS Library is particularly useful in developing drugs targeting protein-protein interactions. Seoul-Fluor : Seoul-Fluor is a fluorescent probe technology developed by SPARK Biopharma. It provides high-sensitivity and high-selectivity fluorescent probes for in vivo molecular imaging. Seoul-Fluor allows real-time observation of specific molecules or processes within cells, making it valuable for studying drug mechanisms of action and disease diagnostics. FITGE (Fluorescence Imaging-based Target Gene Expression) / TS-FITGE : FITGE and its improved version, TS-FITGE (Target-Specific FITGE), are technologies for real-time monitoring of gene expression. These techniques convert the expression levels of specific genes into fluorescent signals for observation. TS-FITGE offers more precise tracking of target gene expression, making it an essential tool for drug screening and disease research.

Private

Biotech